Vonjo® (pacritinib)
for Myelofibrosis
Vonjo (pacritinib) is a kinase inhibitor used to treat myelofibrosis with low platelet counts (cytopenic myelofibrosis) by reducing spleen volume. It works by blocking overactive kinases, including JAK2, FLT3, and IRAK1, which are involved in signaling pathways that cause inflammation in the bone marrow and spleen enlargement.
